Loading, please wait...
| REQUEST PARKING » | MAP & DIRECTIONS » |
RESIDENT SEMINAR SCHEDULE
Wednesday, December 2, 2020
St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis
Academic Research Building (ARB) and Virtually
|
|
ARB 337
|
ARB 406
|
ARB 469
|
|
SESSION 1
12:15 pm – 1:00 pm
|
Elizabeth Sundberg, Pharm.D.
Non-insulin Therapies in Type 1 Diabetes Mellitus |
Katie Riggs, Pharm.D.
Managing of Acute Pain in Patients with Opioid Use Disorder |
Kalee Huddleston. Pharm.D.
Sodium Glucose Transporter-2 (SGLT2) Inhibitors in Heart Failure |
|
1:00 pm – 1:05 pm
|
Break for Transition between Speakers
|
||
|
SESSION 2
1:05 pm – 1:50 pm
|
Sarah Singer, Pharm.D.
Anticoagulation Needs in COVID-19 |
Nicole Nehring, Pharm.D.
The Controversy of Beta-Blockers in COPD: Do They Help or Harm? |
Bailey Archer, Pharm.D.
Safety of Concomitant Use of Linezolid with Serotonergic and Adrenergic Agents |
Please join us for the seventh Resident Seminar session of the 2020-2021 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in the classrooms in the Academic & Research Building (ARB) on the third and fourth floors, as well as virtually.
* Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned is 1.50 contact hours. Participants must complete an evaluation to receive credit.
REGISTRATION & PARKING INFORMATION
Live registrations are submitted by RPDs and through survey monkey only. Due to a limited number of live available classroom spaces, a maximum of 22 people are allowed per classroom. Virtual registrations are limitless and completed through survey monkey. Please note, this event has multiple concurrent sessions.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 5:00 PM on Friday, November 27, 2020 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
HANDOUTS: Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact Nicole Fields at Nicole.Fields@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close December 9, 2020 at 11:59 PM (CDT).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Dec 2, 2020 12:00 PM - 02:00 PM
Fee
$0.00
CE Hours
4.50
Activity Type
- Knowledge
Discuss the background of Type 1 Diabetes Mellitus (T1DM) and the current guideline recommended treatment. Many agents beyond insulin have been studied in T1DM that have shown weight loss, insulin dose reduction, and improved glycemic control. Understanding how the benefits of these new agents fit into T1DM treatment is necessary to continue optimizing treatment of Type 1 diabetic patients. In addition to benefits, understanding the risks of these new agents such as hypoglycemia and diabetic ketoacidosis are just as important. This presentation will review the data supporting alternative medications in T1DM. The goal is to understand the strengths and limitations of these therapies and recognize future directions for T1DM treatment.
Objectives
- Identify the limitations of current therapies available to patients with type 1 diabetes mellitus (T1DM)
- List the alternative agents currently approved for use in T1DM worldwide.
- Given a patient case, select an appropriate non-insulin adjunctive agent for the treatment of T1DM.
Speaker(s)/Author(s)
|
Elizabeth Sundberg, Pharm.D. |
Activity Number
0033-0000-20-082-L01-P
Date:
12/02/20
Time:
12:15 PM - 01:50 PM
CE Hours
0.75
Location
ARB 337 and Virtually
The purpose of this presentation is to provide guidance on developing a more standardized approach to managing acute pain for patients with opioid use disorder (OUD) receiving medication-assisted treatment (MAT). We will review the FDA-approved medications for OUD and how to appropriately manage acute pain in patients receiving these agents. We will compare current literature on the different analgesic treatment strategies for these patients, including non-pharmacologic therapy, non-opioid analgesics, and the addition of opioid analgesics. We will discuss the differences between managing acute pain related to injury, illness, or surgery and how this may impact the selection and duration of analgesic in this patient population. The goal for this personalized approach is to provide effective and safe pain management for patients with OUD receiving MAT while preventing opioid withdrawal and relapse.
Speaker(s)/Author(s)
|
Katie Riggs, Pharm.D. |
Activity Number
0033-0000-20-083-L01-P
Date:
12/02/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 406 and Virtual
The purpose of this presentation is to evaluate current literature on sodium glucose transporter-2 (SGLT2) inhibitors as treatment options in patients with heart failure without diabetes.
Throughout this presentation the potential mechanism of action of SGLT2 inhibitors and guideline recommendations for use of SGLT2 inhibitors in patients with heart failure will be discussed. There will also be a review of clinically relevant trials such as the EMPA-REG Outcome, CANVAS and DECLARE-TIMI trials which led to the development of the DAPA-HF and EMPEROR-reduced trials. The DAPA-HF and EMPEROR-reduced trials provide evidence that SGLT2 inhibitors may be reasonable options for the treatment of heart failure in patients without diabetes. This presentation will also cover future trials that may provide further input on the treatment of heart failure in patients without diabetes. The overall goal for the audience is to discuss current literature on SGLT2 inhibitor use in patients with heart failure and then design a patient-centered medication regimen for the treatment of heart failure in patients without diabetes.
Objectives
- State current guideline recommendations for preferred treatment in patients with type 2 diabetes and established heart failure.
- Describe the results of recent trials looking at treatment with SGLT2 inhibitors in heart failure patients without diabetes.
- Identify an appropriate treatment strategy for a patient without diabetes who has heart failure
Speaker(s)/Author(s)
|
Kalee Huddleston. Pharm.D. |
Activity Number
0033-0000-20-080-L01-P
Date:
12/02/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 469 and Virtually
This session will review the current data on the occurrence of VTE and recommendations for VTE prophylaxis in patients with COVID-19. The proposed mechanism for VTE and potential markers for increased VTE risk in the setting of COVID-19 will be discussed. An emphasis will be placed on the decision to start therapeutic anticoagulation versus continue standard of care VTE prophylaxis in the inpatient setting.
Objectives
- Describe the pathophysiology leading to increased incidence of venous thromboembolism (VTE) in COVID-19.
- Identify risk factors for VTE in a patient with COVID-19.
Speaker(s)/Author(s)
|
Sarah Singer, Pharm.D. |
Activity Number
0033-0000-20-084-L01-P
Date:
12/02/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 337 and Virtually
Some healthcare providers have been reluctant to use beta-blockers in patients with lung disease, such as chronic obstructive pulmonary disease (COPD) or asthma. Patients with COPD who are indicated for beta-blocker therapy have often been under-treated due to fear of bronchospasm and exacerbations. However several observational studies suggest the use of beta-blockers in patients with moderate-to-severe COPD can be helpful and reduce exacerbations and mortality. Recently, a randomized trial comparing metoprolol succinate versus placebo in patients with COPD was published and offers new evidence to determine beta blocker use with contradictory results.
Objectives
- Identify limitations to the randomized controlled trial on the use of beta-blocker therapy in patients with COPD.
- Summarize the results of the observational trials and randomized controlled trial on the use of beta-blockers in COPD regarding overall harm versus benefit.
Speaker(s)/Author(s)
|
Nicole Nehring, Pharm.D. |
Activity Number
0033-0000-20-081-L01-P
Date:
12/02/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ABR 406 and Virtually
I will be discussing the interactions between linezolid and serotonergic agents and linezolid and adrenergic agents and the complications that can arise when administered concomitantly. I will provide a thorough review of the literature to help my audience better understand when it is appropriate to give these medications together and how to do that. The goal of this presentation is for the audience to have a better understanding of when linezolid and serotonergic and adrenergic agents can be given concomitantly.
Objectives
- Identify and describe serotonin syndrome.
- Summarize what the literature recommends when initiating linezolid concomitantly with serotonergic and/or adrenergic agents.
Speaker(s)/Author(s)
|
Bailey Archer, Pharm.D. |
Activity Number
0033-0000-20-085-L01-P
Date:
12/02/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 469 and Virtually
